Zacks Investment Research upgraded shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) from a sell rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada. “
SRRA has been the subject of a number of other reports. ValuEngine raised shares of ProNAi Therapeutics from a strong sell rating to a sell rating in a research note on Friday, September 1st. Jefferies Group LLC reissued a hold rating on shares of ProNAi Therapeutics in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $4.00.
ProNAi Therapeutics (NASDAQ SRRA) opened at $2.34 on Tuesday. ProNAi Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.44.
ProNAi Therapeutics (NASDAQ:SRRA) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.03. sell-side analysts forecast that ProNAi Therapeutics will post -0.85 earnings per share for the current fiscal year.
WARNING: “ProNAi Therapeutics, Inc. (SRRA) Rating Increased to Hold at Zacks Investment Research” was posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/pronai-therapeutics-inc-srra-rating-increased-to-hold-at-zacks-investment-research/1782486.html.
An institutional investor recently bought a new position in ProNAi Therapeutics stock. FMR LLC bought a new position in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of ProNAi Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 55.65% of the company’s stock.
ProNAi Therapeutics Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with our FREE daily email newsletter.